A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer CellsYuhong Jiang, David P. Fairlie|Journal of Pharmacology and Experimental Therapeutics|2017Cited by 66
Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR TransactivationYuhong Jiang, Canquan Mao|Frontiers in Pharmacology|2021Cited by 24
Genome editing of PAR2 through targeted delivery of CRISPR-Cas9 system for alleviating acute lung inflammation via ERK/NLRP3/IL-1β and NO/iNOS signallingXin Zhuo, Yuhong Jiang|Acta Pharmaceutica Sinica B|2023Cited by 11
Dual‐functional Nanosized Albumin Facilitates CRISPR‐Cas9‐PAR2 to Mitigate Cytokine Storm via TLR4 and Pyroptosis SignalingJianbin Li, Yuhong Jiang|Small|2024Cited by 5